These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 11668425

  • 1. Clinical monitoring of hirudin and direct thrombin inhibitors.
    Nowak G.
    Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
    [Abstract] [Full Text] [Related]

  • 2. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G, Roser M, Nauck M.
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [Abstract] [Full Text] [Related]

  • 3. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
    Moser M, Ruef J, Peter K, Kohler B, Gulba DC, Paterna N, Nordt T, Kübler W, Bode C.
    J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
    [Abstract] [Full Text] [Related]

  • 4. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS, Khan AI, Greilich PE, Kroll MH.
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [Abstract] [Full Text] [Related]

  • 5. Quantitative determination of hirudin in blood and body fluids.
    Nowak G, Bucha E.
    Semin Thromb Hemost; 1996 Feb; 22(2):197-202. PubMed ID: 8807717
    [Abstract] [Full Text] [Related]

  • 6. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A, Gouin I, Samama MM.
    Ann Biol Clin (Paris); 2000 Feb; 58(5):575-9. PubMed ID: 11022100
    [Abstract] [Full Text] [Related]

  • 7. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B, Madlener K, Seelig C, Riess CF, Greinacher A, Müller-Berghaus G.
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [Abstract] [Full Text] [Related]

  • 8. A functional clotting assay to monitor the hirudin dosage.
    Zakir RM, Hoffman W, Bhatt BA, Spillert CR.
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
    [Abstract] [Full Text] [Related]

  • 9. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G, Hoffmann U, Hoffmann I, Harenberg J, Heene DL.
    Dtsch Med Wochenschr; 2000 Jun 02; 125(22):686-91. PubMed ID: 10874895
    [Abstract] [Full Text] [Related]

  • 10. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM.
    Thromb Haemost; 2012 May 02; 107(5):985-97. PubMed ID: 22438031
    [Abstract] [Full Text] [Related]

  • 11. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E, Cortellaro M, Leonardi P, Corradi A, Ravasi F, Bertocchi F.
    Thromb Haemost; 1996 Mar 02; 75(3):407-11. PubMed ID: 8701398
    [Abstract] [Full Text] [Related]

  • 12. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.
    Nowak G.
    Pathophysiol Haemost Thromb; 1996 Mar 02; 33(4):173-83. PubMed ID: 15583446
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G.
    Thromb Res; 1997 Jun 01; 86(5):373-83. PubMed ID: 9211628
    [Abstract] [Full Text] [Related]

  • 14. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
    Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J.
    Clin Appl Thromb Hemost; 2001 Jan 01; 7(1):38-43. PubMed ID: 11190903
    [Abstract] [Full Text] [Related]

  • 15. Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin.
    Lange U, Nowak G, Bucha E.
    Pathophysiol Haemost Thromb; 2001 Jan 01; 33(4):184-91. PubMed ID: 15583447
    [Abstract] [Full Text] [Related]

  • 16. The direct thrombin inhibitor hirudin.
    Greinacher A, Warkentin TE.
    Thromb Haemost; 2008 May 01; 99(5):819-29. PubMed ID: 18449411
    [Abstract] [Full Text] [Related]

  • 17. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K, Cvirn G, Fritsch P, Köstenberger M, Gallistl S, Leschnik B, Muntean W.
    Pediatr Res; 2005 May 01; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H.
    Thromb Haemost; 1997 May 01; 77(5):911-9. PubMed ID: 9184402
    [Abstract] [Full Text] [Related]

  • 19. Comparison of three methods for measuring PEG-hirudin in blood.
    Hoffmann JJ, Janssen WC.
    Blood Coagul Fibrinolysis; 2001 Oct 01; 12(7):577-81. PubMed ID: 11685047
    [Abstract] [Full Text] [Related]

  • 20. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 01; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.